Evaluation of a Fully Automated Assay to Measure C-Telopeptide of Type I Collagen in Serum

Pagani, F.; Bonetti, Graziella; Stefini, Francesca; Panteghini, Mauro

doi:10.1515/cclm.2000.166

Cited by 18 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were 11 patients with a normal iPTH concentration in our study who presumably did not have increased bone resorption. Mean serum β-CTX in those dialysis patients (1.13 µg/l) was within the range of 1.0–1.5 µg/l previously reported in another study [15]for patients with severely reduced glomerular function not yet on dialysis. In that study [15], the patients had however some degree of hyperparathyroidism which obscured the exact estimation of the effect of glomerular retention on serum β-CTX.…”

Section: Discussionsupporting

confidence: 82%

“…Mean serum β-CTX in those dialysis patients (1.13 µg/l) was within the range of 1.0–1.5 µg/l previously reported in another study [15]for patients with severely reduced glomerular function not yet on dialysis. In that study [15], the patients had however some degree of hyperparathyroidism which obscured the exact estimation of the effect of glomerular retention on serum β-CTX. One could speculate that β-CTX values above a range of 1.0–1.2 could be attributed to increased bone resorption but only bone histology data could answer this point definitely.…”

Section: Discussionsupporting

confidence: 82%

“…Interpretation of β-CTX concentrations may be influenced unspecifically by renal failure since β-CTX accumulates with impaired renal function [15]. Thus, it would be important to separate unspecific retention of β-CTX from increased bone resorption in hyperparathyroid bone disease.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of Serum β-Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen as Marker of Bone Resorption in Chronic Hemodialysis Patients

Reichel

Roth²,

Schmidt‐Gayk³

2004

Nephron Clin Pract

View full text Add to dashboard Cite

Background: The carboxy-terminal cross-linking telopeptide of type I collagen (β-CrossLaps, β-CTX) is released into the circulation during degradation of type I collagen and serves as a marker of bone resorption. β-CTX is known to undergo a diurnal rhythm in normal individuals and to accumulate in chronic renal failure. β-CTX has a potential role in noninvasive diagnosis of renal bone disease. Methods: Serum β-CTX was compared to parathyroid hormone (PTH) and other biochemical bone markers in 90 unselected hemodialysis patients. Results: Mean β-CTX was elevated above the normal range (1.72 ± 0.93 µg/l); there were large individual variations. Serum β-CTX was significantly correlated with various PTH assays (r >0.56) and with tartrate-resistant acid phosphatase 5b (TRACP 5b, r = 0.629), bone-specific alkaline phosphatase (r = 0.404) and osteocalcin (r = 0.534, all correlations p < 0.001). The correlation between β-CTX and PTH was significantly higher than the correlation between TRACP 5b and PTH. Several factors which could confound interpretation of serum β-CTX were assessed in further studies: (i) There was no recognizable influence of the time of blood sampling (morning dialysis shift versus afternoon dialysis shift) on serum β-CTX. (ii) Serum β-CTX was not significantly related to residual diuresis of patients. Conclusions: We found a high association between β-CTX and other established markers of bone and calcium metabolism demonstrating the potential utility of β-CTX as marker of bone resorption in renal bone disease. However, further studies employing bone histology are still warranted to exactly define the influence of glomerular retention on serum β-CTX in end-stage renal disease.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Evaluation of Serum β-Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen as Marker of Bone Resorption in Chronic Hemodialysis Patients

Reichel

Roth²,

Schmidt‐Gayk³

2004

Nephron Clin Pract

View full text Add to dashboard Cite

show abstract

“…Serum NTX concentrations were above the upper reference limit in 112 (99.1%) of 113 patients. The mean concentration of serum ␤-CTX was 1.62 g/L, 4.4-fold higher than the value of 0.37 g/L reported in 25 apparently healthy men (25 ). The mean concentrations of serum PYD and DPD were 51.5 and 9.6 nmol/L, 18.4-and 5.1-fold higher than the respective reference values of 2.8 (0.8) and 1.9 (0.4) nmol/L reported for healthy individuals (20 ).…”

Section: Serum Ntx and Other Bone Markers In Hd Patientscontrasting

confidence: 67%

Serum Concentrations of Cross-Linked N-Telopeptides of Type I Collagen: New Marker for Bone Resorption in Hemodialysis Patients

et al. 2005

View full text Add to dashboard Cite

Background: Urinary cross-linked N-telopeptide of type I collagen (NTX) is a reliable bone resorption marker in patients with metabolic bone disease. We assessed a clinically available serum NTX assay suitable for anuric patients on hemodialysis (HD). Methods: Serum concentrations of NTX, C-terminal telopeptide of type I collagen (␤-CTX), pyridinoline (PYD), and deoxypyridinoline (DPD) were determined as bone resorption markers, and those of bone alkaline phosphatase (BAP) and intact osteocalcin (OC) as bone formation markers, in 113 male HD patients (mean age, 59.3 years; mean HD duration, 67.7 months). Each patient's bone mineral density (BMD) in the distal third of the radius was measured twice, with a 2-year interval between measurements, by dual-energy x-ray absorptiometry. Results: Serum NTX correlated significantly with ␤-CTX, PYD, DPD, BAP, and intact OC. NTX, as well as ␤-CTX, PYD, DPD, BAP, and intact OC, correlated significantly with BMD at the time of measurement. NTX, ␤-CTX, and DPD correlated significantly with the annual change in BMD during the 2-year period thereafter, in contrast to PYD, BAP, and intact OC. Patients in the highest quartile of serum NTX concentrations showed the fastest rate of bone loss. The sensitivity and specificity for detecting rapid bone loss were 48% and 83%, respectively, for serum NTX.

show abstract

“…Most of these patients have hyperparathyroidism with consecutive activation of bone turnover; but also the reduced renal clearance rate of serum P-CrossLaps is assumed to contribute to the elevated levels in advanced renal insufficiency [25]. In the present study, we analyzed patients with normal renal function, and only few had moderate renal impairment, while parathyroid hormone levels were normal or borderline-elevated in both groups (Table 2).…”

Section: Discussionmentioning

confidence: 95%

Lower serum beta-CrossLaps in male cardiac transplant recipients treated without prednisolone

et al. 2003

View full text Add to dashboard Cite

Post-transplantation bone disease is a frequent problem after successful cardiac transplantation. We performed a cross-sectional analysis of male heart transplant recipients in the late post-transplantation period. Nine patients (group A) had received immunosuppressive therapy with cyclosporin A and mycophenolate mofetil (steroid-free treatment), and 12 patients (group B) remained on triple-drug therapy, which included glucocorticosteroids. Bone mineral density status was analyzed by osteodensitometry and by markers of bone turnover. Osteopenia was common in both groups (44.4% in group A and 50% in group B) as was osteoporosis (30% and 33.3% in groups A and B, respectively). P-CrossLaps were significantly lower in sera of cardiac transplant recipients on double immunosuppressive (i.e., glucocorticosteroid-free) regimen than in sera of patients on triple-drug therapy (428.3 f 109.4 vs 661.7 k 337.0 pg/ml, P < 0.05).Lower serum /I-CrossLaps levels in patients undergoing glucocorticosteroid-free treatment may indicate a lower risk of bone deterioration in the long term.

show abstract

Evaluation of a Fully Automated Assay to Measure C-Telopeptide of Type I Collagen in Serum

Cited by 18 publications

References 8 publications

Evaluation of Serum β-Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen as Marker of Bone Resorption in Chronic Hemodialysis Patients

Evaluation of Serum β-Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen as Marker of Bone Resorption in Chronic Hemodialysis Patients

Serum Concentrations of Cross-Linked N-Telopeptides of Type I Collagen: New Marker for Bone Resorption in Hemodialysis Patients

Lower serum beta-CrossLaps in male cardiac transplant recipients treated without prednisolone

Contact Info

Product

Resources

About